The questions patients ask most often about treatments, the process, and ordering. If something is missing, the team can answer it directly.
Semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring hormone involved in appetite and blood sugar regulation. It can help reduce appetite, increase feelings of fullness, and support improved glucose control. By helping people feel satisfied for longer, it may support gradual and sustained weight management when combined with appropriate nutrition, physical activity, and lifestyle changes. Semaglutide is generally administered once weekly. Prescription semaglutide is FDA approved for certain medical indications, and treatment should be provided under appropriate medical supervision.
Tirzepatide is a dual GIP and GLP-1 receptor agonist that works through two hormone pathways involved in appetite, blood sugar regulation, and metabolic function. It can help decrease appetite, increase feelings of fullness, and support reduced food intake. Clinical studies have demonstrated substantial weight reduction in eligible patients when treatment is combined with appropriate nutrition and lifestyle changes. Tirzepatide is administered as a once weekly injection, with dosing typically adjusted gradually based on response and tolerability. Prescription tirzepatide is FDA approved for certain medical indications and should be used under appropriate medical supervision.
Retatrutide is an investigational triple receptor agonist that targets GLP-1, GIP, and glucagon receptors. This distinguishes it from semaglutide, which targets GLP-1 receptors, and tirzepatide, which targets GIP and GLP-1 receptors. Researchers are studying retatrutide for its potential effects on appetite regulation, energy balance, glucose metabolism, and body weight. Clinical trials have reported promising weight reduction and metabolic effects, but research into its safety, effectiveness, side effects, and appropriate dosing is still ongoing. Retatrutide is not currently FDA approved for weight management or other medical use and remains an investigational treatment.
Important correction for your product description: Retatrutide ko jo description aapne diya tha usme “two key metabolic pathways (GLP-1 and GIP)” likha hai. Ye Tirzepatide ka mechanism describe karta hai. Retatrutide is a triple agonist targeting GLP-1, GIP and glucagon receptors, so product page par bhi ye line correct karni chahiye.
You complete a medical evaluation, the information is reviewed by the medical team, you receive a personalized plan, and then care continues with scheduled follow-ups.
Go straight to the online store and reorder your current treatment. You do not need to repeat the full informational journey.
Yes. Plans are built from your medical history, goals, and response over time, and are adjusted as your care progresses.
Any medication can cause side effects. Common GLP-1 related effects are discussed during your review, and dosing is adjusted to manage tolerance.
Start in the online store or contact the team, and your plan will be organised around your medical review.
Returning patients reorder in the store. New patients receive a plan built from their medical review.

Advanced medical weight-loss care. This site is informational and does not provide medical advice, diagnosis, or treatment guarantees.
© 2026 Amino Treatment . All rights reserved.